InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.510 0.015 (3.03%)+
Announcement
Release
24 Aug 2026 8:09AM
Price at Release
$0.495
Full Release
download
Summary
Cyclopharm Limited's half-yearly report for the period ending June 30, 2026, highlights a challenging financial landscape with a reported net loss of AUD 8.79 million. The report details operating cash outflows amounting to AUD 7.69 million, driven by payments to suppliers and employees exceeding receipts from customers. Despite a significant cash inflow from the issuance of shares amounting to AUD 14.18 million, the company's net assets increased to AUD 31.86 million compared to December 2025. Cyclopharm continues to invest in property, plant, and equipment with a capital expenditure of AUD 191,203 during the period. The company's balance sheet shows total assets of AUD 49.68 million and liabilities of AUD 17.81 million. The equity includes contributed equity of AUD 100.58 million and accumulated losses of AUD 73.87 million. The report also notes the impact of foreign currency translation and highlights management's strategic focus on leveraging its Technegas technology and expanding market presence.
Key Points
  • Net loss for half-year ended 30 June 2026 was AUD 8.79 million.
  • Operating cash outflows amounted to AUD 7.69 million.
  • Share issuance brought in AUD 14.18 million.
  • Net assets increased to AUD 31.86 million by June 2026.
  • Investments in property, plant, and equipment totaled AUD 191,203.
  • Total assets reported at AUD 49.68 million; liabilities at AUD 17.81 million.
  • Contributed equity stands at AUD 100.58 million with accumulated losses at AUD 73.87 million.
  • Focus on leveraging Technegas technology and market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.